Chenodeoxycholic Acid (Synonyms: 鵝去氧膽酸; CDCA)

目錄號(hào): HY-76847 純度: 99.90%: FAQs
Data Sheet SDS COA 產(chǎn)品使用指南

摩爾計(jì)算器

Chenodeoxycholic Acid 是一種疏水初級(jí)膽汁酸，能夠活化核受體 FXR，該受體與膽固醇代謝有關(guān)。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

Chenodeoxycholic Acid Chemical Structure

CAS No. : 474-25-9

1. 客戶無(wú)需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2. 同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3. 試用裝只面向終端客戶。

規(guī)格	價(jià)格	是否有貨
10 mM * 1 mL in DMSO	￥550	In-stock
100 mg	￥500	In-stock
500 mg	￥700	In-stock
1 g	￥900	In-stock
5 g	￥1300	In-stock
10 g		詢價(jià)
50 g		詢價(jià)

or 大包裝詢價(jià)

* Please select Quantity before adding items.

Customer Review

Other Forms of Chenodeoxycholic Acid:

Chenodeoxycholic Acid-d₄ In-stock
Chenodeoxycholic acid-¹³C In-stock
Chenodeoxycholic acid-d₅ In-stock
Chenodeoxycholic Acid-d₉ 詢價(jià)
Chenodeoxycholic acid sodium 詢價(jià)
Chenodeoxycholic Acid (Standard) 詢價(jià)

MCE 顧客使用本產(chǎn)品發(fā)表的 13 篇科研文獻(xiàn)

•Nature. 2024 Dec 18.
•Cell Res. 2019 Mar;29(3):193-205. [Abstract]
•Cell Host Microbe. 2024 Feb 14;32(2):191-208.e9. [Abstract]
•Research (Wash D C). 2022 Nov 2;2022:9784081. [Abstract]
•Sci Total Environ. 2023 Apr 15. [Abstract]
•J Agric Food Chem. 2023 Nov 10. [Abstract]
•Phytomedicine.2023 Sep:118:154971. [Abstract]
•Phytother Res. 2021 Mar;35(3):1495-1507. [Abstract]
•Int J Mol Sci. 2023 Aug 30, 24(17), 13494.
•Aquaculture. 2023 Sep 18, 740123.
•J Biol Chem. 2024 Sep 12:107765. [Abstract]
•Am J Hypertens. 2022 Jul 6. [Abstract]

•SSRN. 2022 Jan 26.

Chenodeoxycholic Acid 相關(guān)產(chǎn)品

•相關(guān)化合物庫(kù):

•同靶點(diǎn)產(chǎn)品:

•同靶點(diǎn)蛋白產(chǎn)品:

生物活性
實(shí)驗(yàn)參考方法
純度 & 產(chǎn)品資料
參考文獻(xiàn)

生物活性

Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

IC₅₀ & Target

Human Endogenous Metabolite

細(xì)胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A549	IC₅₀	> 200 μM Compound: CDCA	Anticancer activity against human A549 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human A549 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
Caco-2	IC₅₀	106 μM Compound: CDCA	Cytotoxicity against human Caco2 cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human Caco2 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 24332653]
CHO	EC₅₀	15.6 μM Compound: CDCA	Agonist activity at recombinant human TGR5 expressed in CHO cells assessed as increase in cAMP accumulation after 30 mins by TR-FRET assay Agonist activity at recombinant human TGR5 expressed in CHO cells assessed as increase in cAMP accumulation after 30 mins by TR-FRET assay	[PMID: 31268316]
CHO	EC₅₀	6.71 μM Compound: 4, CDCA	Agonist activity at human TGR5 expressed in CHO cells by luciferase assay Agonist activity at human TGR5 expressed in CHO cells by luciferase assay	[PMID: 18307294]
CHO	EC₅₀	6.71 μM Compound: 2, CDCA	Agonist activity at human TGR5 expressed in CHO cells after 5 hrs by CRE-driven luciferase reporter gene assay Agonist activity at human TGR5 expressed in CHO cells after 5 hrs by CRE-driven luciferase reporter gene assay	[PMID: 17685603]
COS-1	EC₅₀	13 μM Compound: 4, CDCA	Agonist activity at human FXR expressed in COS1 cells by luciferase assay Agonist activity at human FXR expressed in COS1 cells by luciferase assay	[PMID: 18307294]
COS-1	EC₅₀	13 μM Compound: 2, CDCA	Agonist activity at human FXR expressed in COS1 cells after 5 hrs by CRE-driven luciferase reporter gene assay Agonist activity at human FXR expressed in COS1 cells after 5 hrs by CRE-driven luciferase reporter gene assay	[PMID: 17685603]
COS-1	EC₅₀	13 μM Compound: 3, CDCA	Agonist activity at FXR expressed in COS1 cells by cell-based bioluminescence assay Agonist activity at FXR expressed in COS1 cells by cell-based bioluminescence assay	[PMID: 20014870]
GBM	IC₅₀	> 50 μM Compound: 1c, CDCA, chenodeoxycholic acid	Cytotoxicity against human GBM cells after 24 hrs by neutral red uptake assay Cytotoxicity against human GBM cells after 24 hrs by neutral red uptake assay	[PMID: 20381215]
HCT-116	IC₅₀	> 200 μM Compound: CDCA	Anticancer activity against human HCT-116 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human HCT-116 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
HCT-116	IC₅₀	> 50 μM Compound: 1c, CDCA, chenodeoxycholic acid	Cytotoxicity against human HCT116 cells after 24 hrs by neutral red uptake assay Cytotoxicity against human HCT116 cells after 24 hrs by neutral red uptake assay	[PMID: 20381215]
HEK293	EC₅₀	11.7 μM Compound: 3, CDCA	Agonist activity at human recombinant FXR by transactivation of TK-MH100x4-LUC reporter gene in HEK293 cells Agonist activity at human recombinant FXR by transactivation of TK-MH100x4-LUC reporter gene in HEK293 cells	[PMID: 16617018]
HEK293	EC₅₀	16.8 μM Compound: CDCA	Agonist activity at full length mouse FXR/RXRalpha expressed in human HEK293 cells assessed as induction of transcriptional activity after 18 hrs by dual luciferase reporter gene assay Agonist activity at full length mouse FXR/RXRalpha expressed in human HEK293 cells assessed as induction of transcriptional activity after 18 hrs by dual luciferase reporter gene assay	[PMID: 22014750]
HEK293	EC₅₀	16.8 μM Compound: 2, CDCA	Agonist activity at mouse FXR expressed in HEK293 cells co-expressing mouse RXRalpha and ECRE-luc by luciferase reporter gene assay Agonist activity at mouse FXR expressed in HEK293 cells co-expressing mouse RXRalpha and ECRE-luc by luciferase reporter gene assay	[PMID: 22018919]
HEK293	EC₅₀	27 μM Compound: 5, CDCA	Agonist activity at human recombinant FXR expressed in HEK293 cells coexpressing CMX-GAL4N by luciferase reporter gene assay Agonist activity at human recombinant FXR expressed in HEK293 cells coexpressing CMX-GAL4N by luciferase reporter gene assay	[PMID: 22583617]
HEK293	EC₅₀	27 μM Compound: CDCA	Agonistic activity at FXR in HEK293 cells by GAL4 transactivation activity Agonistic activity at FXR in HEK293 cells by GAL4 transactivation activity	[PMID: 17292610]
HEK293	EC₅₀	6.1 μM Compound: 2, CDCA	Agonist activity at human GPBAR1 expressed in HEK293 cells assessed as increase in intracellular cAMP level after 30 mins by cAMP-Glo assay Agonist activity at human GPBAR1 expressed in HEK293 cells assessed as increase in intracellular cAMP level after 30 mins by cAMP-Glo assay	[PMID: 25735208]
HEK-293T	EC₅₀	> 150 μM Compound: CDCA	Agonist activity at VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay Agonist activity at VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay	[PMID: 26774929]
HEK-293T	IC₅₀	> 50 μM Compound: CDCA	Antagonist activity against VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as inhibition of 1,25-dihydroxyvitamin D3-induced SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay Antagonist activity against VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as inhibition of 1,25-dihydroxyvitamin D3-induced SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay	[PMID: 26774929]
HeLa	EC₅₀	18 μM Compound: 1, CDCA	Agonist activity at human full length FXR expressed in HeLa cells cotransfected with pSG5-human RXR after 24 hrs by Dual-Glo luciferase reporter gene assay Agonist activity at human full length FXR expressed in HeLa cells cotransfected with pSG5-human RXR after 24 hrs by Dual-Glo luciferase reporter gene assay	[PMID: 25934227]
HeLa	EC₅₀	18 μM Compound: 1, CDCA	Agonist activity at human FXR expressed in human HeLa cells assessed as receptor activation by BSEP promoter-driven firefly luciferase reporter gene assay Agonist activity at human FXR expressed in human HeLa cells assessed as receptor activation by BSEP promoter-driven firefly luciferase reporter gene assay	[PMID: 25255039]
HepG2	EC₅₀	20 μM Compound: 1; CDCA	Transactivation of human FXR (unknown origin) expressed in HepG2 cells co-expressing pSG5RXR/pGL4.70 after 24 hrs post transfection by luciferase reporter gene assay Transactivation of human FXR (unknown origin) expressed in HepG2 cells co-expressing pSG5RXR/pGL4.70 after 24 hrs post transfection by luciferase reporter gene assay	[PMID: 30996771]
HET-1A	CC₅₀	216 μM Compound: 1, CDCA	Cytotoxicity against human HET-1A cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human HET-1A cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 20713311]
HT-1080	IC₅₀	130.1 μM Compound: CDCA	Cytotoxicity against human HT1080 cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human HT1080 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 24332653]
HT-29	IC₅₀	> 200 μM Compound: CDCA	Anticancer activity against human HT-29 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human HT-29 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
HT-29	IC₅₀	> 80 μM Compound: CDCA	Antiproliferative activity against human HT-29 cells after 48 hrs by SRB assay Antiproliferative activity against human HT-29 cells after 48 hrs by SRB assay	[PMID: 27448915]
Huh-7	IC₅₀	> 200 μM Compound: CDCA	Anticancer activity against human Huh-7 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human Huh-7 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
KMS-11	IC₅₀	> 50 μM Compound: 1c, CDCA, chenodeoxycholic acid	Cytotoxicity against human KMS11 cells after 24 hrs by neutral red uptake assay Cytotoxicity against human KMS11 cells after 24 hrs by neutral red uptake assay	[PMID: 20381215]
LoVo	IC₅₀	> 200 μM Compound: CDCA	Anticancer activity against human LoVo cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human LoVo cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
MGC-803	IC₅₀	> 200 μM Compound: CDCA	Anticancer activity against human MGC-803 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human MGC-803 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
NCI-H716	EC₅₀	30 μM Compound: 1, CDCA	Agonist activity at human TGR5 receptor expressed in NCI-H716 cells assessed as intracellular cAMP level by TR-FRET assay Agonist activity at human TGR5 receptor expressed in NCI-H716 cells assessed as intracellular cAMP level by TR-FRET assay	[PMID: 21459580]
NCI-H716	EC₅₀	33 μM Compound: CDCA	Agonist activity at TGR5 in human NCI-H716 cells assessed as increase in cAMP accumulation after 60 mins by HTR-FRET assay Agonist activity at TGR5 in human NCI-H716 cells assessed as increase in cAMP accumulation after 60 mins by HTR-FRET assay	[PMID: 31268316]
NCI-H716	EC₅₀	6.7 μM Compound: 2, CDCA	Agonist activity at TGR5 expressed in NCI-H716 cells assessed as cAMP level after 60 mins by FRET analysis Agonist activity at TGR5 expressed in NCI-H716 cells assessed as cAMP level after 60 mins by FRET analysis	[PMID: 24900463]
PC-3M	IC₅₀	> 80 μM Compound: CDCA	Antiproliferative activity against human PC3M cells after 48 hrs by SRB assay Antiproliferative activity against human PC3M cells after 48 hrs by SRB assay	[PMID: 27448915]
RKO	IC₅₀	> 200 μM Compound: CDCA	Anticancer activity against human RKO cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human RKO cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
SK-HEP1	IC₅₀	> 200 μM Compound: CDCA	Anticancer activity against human SK-HEP1 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human SK-HEP1 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
SW480	IC₅₀	> 200 μM Compound: CDCA	Anticancer activity against human SW480 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human SW480 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]

體外研究
(In Vitro)

Cheonodeoxycholic acid (CDCA) 和 Deoxycholic acid (DCA) 均抑制 11 beta HSD2，IC₅₀ 值分別為 22 mM 和 38 mM，并引起皮質(zhì)醇依賴性核轉(zhuǎn)位并增加鹽皮質(zhì)激素受體 (MR) 的轉(zhuǎn)錄活性)^[1]。Cheonodeoxycholic acid 能夠通過(guò)激活膜 G 蛋白偶聯(lián)受體 (TGR5) 依賴性通路誘導(dǎo)細(xì)胞周期蛋白 D1 蛋白和 mRNA 表達(dá)顯著增加，從而刺激 Ishikawa 細(xì)胞生長(zhǎng)^[2]。在培養(yǎng)的人肝母細(xì)胞瘤細(xì)胞系 Hep G2^[3]中，Chenodeoxycholic Acid (CDCA) 可將 LDL 受體 mRNA 水平提高約 4 倍，將 HMG-CoA 還原酶和 HMG-CoA 合酶的 mRNA 水平提高兩倍。布美他尼、BaCl₂ 和囊性纖維化跨膜電導(dǎo)調(diào)節(jié)劑 (CFTR) 抑制劑 CFTRinh-172 可抑制鵝脫氧膽酸誘導(dǎo)的 Isc (≥67%)。Chenodeoxycholic Acid 刺激的 Isc 被腺苷酸環(huán)化酶抑制劑 MDL12330A 降低了 43%，而 Chenodeoxycholic Acid 增加了細(xì)胞內(nèi) cAMP 濃度^[4]。Chenodeoxycholic Acid 處理可激活 C/EBPβ，如其在 HepG2 細(xì)胞中的磷酸化、核積累和表達(dá)增加所示。Cheonodeoxycholic acid 增強(qiáng)熒光素酶基因從含有-1.65-kb GSTA2 啟動(dòng)子的構(gòu)建體轉(zhuǎn)錄，該啟動(dòng)子含有 C/EBP 反應(yīng)元件 (pGL-1651)。Chenodeoxycholic Acid 處理可激活 AMP 活化蛋白激酶 (AMPK)，從而導(dǎo)致細(xì)胞外信號(hào)調(diào)節(jié)激酶 1/2 (ERK1/2) 激活，使用 AMPKα 顯性失活突變體和化學(xué)抑制劑的實(shí)驗(yàn)結(jié)果證明了這一點(diǎn)^[5]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

392.57

Formula

C₂₄H₄₀O₄

CAS 號(hào)

474-25-9

性狀

固體

顏色

White to off-white

中文名稱

鵝去氧膽酸

結(jié)構(gòu)分類

Steroids

初始來(lái)源

微生物

運(yùn)輸條件

Room temperature in continental US; may vary elsewhere.

儲(chǔ)存方式

RT, protect from light

In solvent	-80°C	2 years
	-20°C	1 year

溶解性數(shù)據(jù)

細(xì)胞實(shí)驗(yàn)：

DMSO 中的溶解度 : ≥ 50 mg/mL (127.37 mM; 吸濕的 DMSO 對(duì)產(chǎn)品的溶解度有顯著影響，請(qǐng)使用新開(kāi)封的 DMSO)

0.1 M NaOH 中的溶解度 : 50 mg/mL (127.37 mM; ultrasonic and adjust pH to 8 with NaOH)

* "≥" means soluble, but saturation unknown.

配制儲(chǔ)備液

濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg

1 mM	2.5473 mL	12.7366 mL	25.4732 mL
5 mM	0.5095 mL	2.5473 mL	5.0946 mL
10 mM	0.2547 mL	1.2737 mL	2.5473 mL

查看完整儲(chǔ)備液配制表

* 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲(chǔ)備液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?年內(nèi)使用，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?年內(nèi)使用。

摩爾計(jì)算器
稀釋計(jì)算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

濃度 _(start)

體積 _(start)

濃度 _(final)

體積 _(final)

動(dòng)物實(shí)驗(yàn)：

請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥方式選擇適當(dāng)?shù)娜芙夥桨浮?

以下溶解方案都請(qǐng)先按照 In Vitro 方式配制澄清的儲(chǔ)備液，再依次添加助溶劑：
——為保證實(shí)驗(yàn)結(jié)果的可靠性，澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過(guò)加熱和/或超聲的方式助溶

方案一

請(qǐng)依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (6.37 mM); 懸濁液; 超聲助溶

此方案可獲得 2.5 mg/mL的均勻懸濁液，懸濁液可用于口服和腹腔注射。
以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水定容至 1 mL。
生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
方案二

請(qǐng)依序添加每種溶劑： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.37 mM); 澄清溶液

此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液。
以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液中，混合均勻。
2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。
方案三

請(qǐng)依序添加每種溶劑： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (6.37 mM); 澄清溶液

此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液，此方案實(shí)驗(yàn)周期在半個(gè)月以上的動(dòng)物實(shí)驗(yàn)酌情使用。
以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 900 μL玉米油中，混合均勻。

以下溶解方案，請(qǐng)直接配制工作液。建議現(xiàn)用現(xiàn)配，在短期內(nèi)盡快用完。以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過(guò)加熱和/或超聲的方式助溶。

方案一

請(qǐng)依序添加每種溶劑： 20% HP-β-CD in Saline
Solubility: ≥ 20 mg/mL (50.95 mM); 澄清溶液

動(dòng)物溶解方案計(jì)算器

請(qǐng)輸入動(dòng)物實(shí)驗(yàn)的基本信息：

給藥劑量

mg/kg

動(dòng)物的平均體重

每只動(dòng)物的給藥體積

μL

動(dòng)物數(shù)量

只

由于實(shí)驗(yàn)過(guò)程有損耗，建議您多配一只動(dòng)物的量

請(qǐng)輸入您的動(dòng)物體內(nèi)配方組成：

DMSO +

Tween-80 +

Saline

如果您的動(dòng)物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過(guò) 2%。

方案所需 助溶劑 包括：DMSO，，均可在 MCE 網(wǎng)站選購(gòu)。，Tween 80，均可在 MCE 網(wǎng)站選購(gòu)。

計(jì)算結(jié)果

工作液所需濃度 : mg/mL

儲(chǔ)備液配制方法 : mg 藥物溶于 μL DMSO（母液濃度為 mg/mL）。

您所需的儲(chǔ)備液濃度超過(guò)該產(chǎn)品的實(shí)測(cè)溶解度，以下方案僅供參考，如有需要，請(qǐng)與 MCE 中國(guó)技術(shù)支持聯(lián)系。

動(dòng)物實(shí)驗(yàn)體內(nèi)工作液的配制方法 : 取 μL DMSO 儲(chǔ)備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。

連續(xù)給藥周期超過(guò)半月以上，請(qǐng)謹(jǐn)慎選擇該方案。

請(qǐng)確保第一步儲(chǔ)備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱（超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。

純度 & 產(chǎn)品資料

純度: 99.90%

選擇批次：

Data Sheet (657 KB) SDS (393 KB)

COA (289 KB) RP-HPLC (218 KB)

產(chǎn)品使用指南 (1538 KB)

參考文獻(xiàn)

[1]. Stauffer AT, et al. Chenodeoxycholic acid and deoxycholic acid inhibit 11 beta-hydroxysteroid dehydrogenase type 2 and cause cortisol-induced transcriptional activation of the mineralocorticoid receptor. J Biol Chem. 2002 Jul 19;277(29):26286-92 [Content Brief]

[2]. Casaburi I, et al. Chenodeoxycholic acid through a TGR5-dependent CREB signaling activation enhances cyclin D1 expression and promotes human endometrial cancer cell proliferation. Cell Cycle. 2012 Jul 15;11(14):2699-710 [Content Brief]

[3]. Kawabe Y, et al. The molecular mechanism of the induction of the low density lipoprotein receptor by chenodeoxycholic acid in cultured human cells. Biochem Biophys Res Commun. 1995 Mar 8;208(1):405-11. [Content Brief]

[4]. Ao M, et al. Chenodeoxycholic acid stimulates Cl(-) secretion via cAMP signaling and increases cystic fibrosis transmembrane conductance regulator phosphorylation in T84 cells. Am J Physiol Cell Physiol. 2013 Aug 15;305(4):C447-56 [Content Brief]

[5]. Noh K, et al. Farnesoid X receptor activation by chenodeoxycholic acid induces detoxifying enzymes through AMP-activated protein kinase and extracellular signal-regulated kinase 1/2-mediated phosphorylation of CCAAT/enhancer binding protein β. Drug Metab [Content Brief]

Kinase Assay ^[1]	Briefly, transfected HEK-293 cells, incubated in charcoal-treated Dulbecco's modified Eagle's medium for 24 h, are washed once with Hanks' solution and resuspended in a buffer containing 100 mM NaCl, 1 mM MgCl₂, 1 mM EDTA, 1 mM EGTA, 250 mMsucrose, 20 mM Tris-HCl, pH 7.4. Cells are lysed by freezing in liquid nitrogen. Dehydrogenase activity is measured in a final volume of 20 μL containing the appropriate concentration of bile acid, 30 nCi of [³H]cortisol, and unlabeled cortisol to a final concentrations of 50 nM. The reaction is started by mixing cell lysate with the reaction mixture. Alternatively, endoplasmic reticulum microsomes are prepared from transfected HEK-293 cells and incubated with reaction mixture containing various concentrations of cortisol and CDCA. Incubation proceeded for 20 min, and the conversion of cortisol to cortisone is determined by thin layer chromatography (TLC). Because of the inaccuracy of the TLC method at low conversion rates and the end-product inhibition of 11βHSD2 at conversion rates higher than 60-70%, only conversion rates between 10 and 60% are considered for calculation. The inhibitory constant IC₅₀ is evaluated using the curve-fitting program. Results are expressed as means±S.E. and consist of at least four independent measurements. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Assay ^[1]	The cell viability is analyzed by incubating transfected HEK-293 cells and CHO cells for 1 h with the corresponding concentration of bile acid and staining with trypan blue. The toxicity of bile acids is analyzed using the tetrazolium salt MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) according to the cell proliferation kit I. No significant differences between control and bile acid-treated cells are obtained in both tests. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
參考文獻(xiàn)	[1]. Stauffer AT, et al. Chenodeoxycholic acid and deoxycholic acid inhibit 11 beta-hydroxysteroid dehydrogenase type 2 and cause cortisol-induced transcriptional activation of the mineralocorticoid receptor. J Biol Chem. 2002 Jul 19;277(29):26286-92 [Content Brief] [2]. Casaburi I, et al. Chenodeoxycholic acid through a TGR5-dependent CREB signaling activation enhances cyclin D1 expression and promotes human endometrial cancer cell proliferation. Cell Cycle. 2012 Jul 15;11(14):2699-710 [Content Brief] [3]. Kawabe Y, et al. The molecular mechanism of the induction of the low density lipoprotein receptor by chenodeoxycholic acid in cultured human cells. Biochem Biophys Res Commun. 1995 Mar 8;208(1):405-11. [Content Brief] [4]. Ao M, et al. Chenodeoxycholic acid stimulates Cl(-) secretion via cAMP signaling and increases cystic fibrosis transmembrane conductance regulator phosphorylation in T84 cells. Am J Physiol Cell Physiol. 2013 Aug 15;305(4):C447-56 [Content Brief] [5]. Noh K, et al. Farnesoid X receptor activation by chenodeoxycholic acid induces detoxifying enzymes through AMP-activated protein kinase and extracellular signal-regulated kinase 1/2-mediated phosphorylation of CCAAT/enhancer binding protein β. Drug Metab [Content Brief]

Chenodeoxycholic Acid 相關(guān)分類

完整儲(chǔ)備液配制表

可選溶劑	濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg	25 mg

DMSO / 0.1 M NaOH	1 mM	2.5473 mL	12.7366 mL	25.4732 mL	63.6829 mL
	5 mM	0.5095 mL	2.5473 mL	5.0946 mL	12.7366 mL
	10 mM	0.2547 mL	1.2737 mL	2.5473 mL	6.3683 mL
	15 mM	0.1698 mL	0.8491 mL	1.6982 mL	4.2455 mL
	20 mM	0.1274 mL	0.6368 mL	1.2737 mL	3.1841 mL
	25 mM	0.1019 mL	0.5095 mL	1.0189 mL	2.5473 mL
	30 mM	0.0849 mL	0.4246 mL	0.8491 mL	2.1228 mL
	40 mM	0.0637 mL	0.3184 mL	0.6368 mL	1.5921 mL
	50 mM	0.0509 mL	0.2547 mL	0.5095 mL	1.2737 mL
	60 mM	0.0425 mL	0.2123 mL	0.4246 mL	1.0614 mL
	80 mM	0.0318 mL	0.1592 mL	0.3184 mL	0.7960 mL
	100 mM	0.0255 mL	0.1274 mL	0.2547 mL	0.6368 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Chenodeoxycholic Acid474-25-9CDCA鵝去氧膽酸FXREndogenous MetaboliteAutophagyNR1H4Inhibitorinhibitorinhibit

產(chǎn)品名稱：			* 需求量：
* 客戶姓名：			* Email：
* 電話：			* 公司或機(jī)構(gòu)名稱：
留言給我們：

產(chǎn)品名稱：			* Lot #：
* 客戶姓名：			* Email：
電話：			* 部門：
* 公司或機(jī)構(gòu)名稱：
留言給我們：

MedChemExpress (MCE) 只為有資質(zhì)的科研機(jī)構(gòu)、醫(yī)藥企業(yè)基于科學(xué)研究或藥證申報(bào)的用途提供醫(yī)藥研發(fā)服務(wù)，不為任何個(gè)人或者非科研性質(zhì)的、非用于藥證申報(bào)使用等其他用途提供服務(wù)。	站點(diǎn)地圖隱私聲明
滬ICP備15051369號(hào)-4 上海工商滬公網(wǎng)安備31011502019417 滬(浦)應(yīng)急管危經(jīng)許[2021]201709(QFYS) 營(yíng)業(yè)執(zhí)照（三證合一）
Copyright ? 2013-2025 MedChemExpress. All Rights Reserved.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Chenodeoxycholic Acid (Synonyms: 鵝去氧膽酸; CDCA)

Customer Review

Other Forms of Chenodeoxycholic Acid:

MCE 顧客使用本產(chǎn)品發(fā)表的 13 篇科研文獻(xiàn)

Chenodeoxycholic Acid 相關(guān)產(chǎn)品

•相關(guān)化合物庫(kù):

•同靶點(diǎn)產(chǎn)品:

•同靶點(diǎn)蛋白產(chǎn)品:

生物活性

實(shí)驗(yàn)參考方法

純度 & 產(chǎn)品資料

參考文獻(xiàn)

摩爾計(jì)算器

稀釋計(jì)算器

Chenodeoxycholic Acid 相關(guān)分類

完整儲(chǔ)備液配制表

Keywords:

您最近查看的產(chǎn)品:

熱門區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
郵箱 *

Sorry, but the email address you supplied was invalid.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Chenodeoxycholic Acid (Synonyms: 鵝去氧膽酸; CDCA)

Customer Review

Other Forms of Chenodeoxycholic Acid:

Chenodeoxycholic Acid 相關(guān)抗體

MCE 顧客使用本產(chǎn)品發(fā)表的 13 篇科研文獻(xiàn)

Chenodeoxycholic Acid 相關(guān)產(chǎn)品

•相關(guān)化合物庫(kù):

•同靶點(diǎn)產(chǎn)品:

•同靶點(diǎn)蛋白產(chǎn)品:

生物活性

實(shí)驗(yàn)參考方法

純度 & 產(chǎn)品資料

參考文獻(xiàn)

Chenodeoxycholic Acid 相關(guān)抗體:

摩爾計(jì)算器

稀釋計(jì)算器

Chenodeoxycholic Acid 相關(guān)分類

完整儲(chǔ)備液配制表

Keywords:

您最近查看的產(chǎn)品:

Request for HNMR Report

Request for HNMR Report

熱門區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z